Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study

Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study

Abstract Background Oral selexipag, a prostacyclin pathway agent (PPA), is effective in patients with pulmonary arterial hypertension (PAH). The objective of this study is to assess the impact of initiating oral selexipag within 12 months of diagnosis on health outcomes. Methods This retrospective c...

Full description

Bibliographic Details
Main Authors: Yuen Tsang, Michael Stokes, Yong‐Jin Kim, Rong Tilney, Sumeet Panjabi
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:The Clinical Respiratory Journal
Subjects:
cost
disease progression
hospitalization
prostacyclin pathway agent
pulmonary arterial hypertension
selexipag
Online Access:https://doi.org/10.1111/crj.13704

Internet

https://doi.org/10.1111/crj.13704

Similar Items